Skip to content

Clinical and Mechanistic Study on the Promotion of Motor Function Recovery in Ischemic Stroke by Transcranial Temporal Interference Stimulation

Clinical and Mechanistic Study on the Promotion of Motor Function Recovery in Ischemic Stroke by Transcranial Temporal Interference Stimulation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600116140
Enrollment
Unknown
Registered
2026-01-06
Start date
2026-02-01
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stroke

Interventions

Group A:1 Hz iTIS over the contralesional Corpus callosum area(CC) and then 10HZ stimulation over the ipsilesional Corpus callosum area
Group B:contralesional sham stimulation and then 10HZ stimulation over the ipsilesional CC
Group C:contralesional real 1 Hz iTIS and then ipsilesional sham stimulation

Sponsors

The First Affiliated Hospital of Soochow University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients with first-onset ischemic stroke; 2. Patients with acute stroke within 2 weeks; 3. Patients with unilateral limb motor dysfunction; 4. Patients with cerebral infarction in the unilateral middle cerebral artery area as indicated by magnetic resonance imaging (MRI); 5. Patients aged between 18 and 80 years old; 6. Patients identified as right-handed based on the Edinburgh Handedness Inventory; 7. Patients with normal auditory function; 8. Patients capable of completing 30 minutes of daily rehabilitation training as required; 9. Patients who have signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with hemorrhagic stroke; 2. Patients with other neurological disorders; 3. Patients with severe aphasia or cognitive impairment; 4. Patients who are about to receive or have already received antidepressant or benzodiazepine treatment; 5. Patients with concurrent cancer, severe lung disease or heart disease; 6. Patients with contraindications to MR, including pacemaker implantation or epilepsy; 7. Those who cannot provide informed consent; 8. Patients who refuse to participate, die or are lost to follow-up during the follow-up period.

Design outcomes

Primary

MeasureTime frame
Fugl-Meyer Assessment(FMA);

Secondary

MeasureTime frame
A multi-modal fMRI data;National Institutes of Health Stroke Scale(NIHSS);Modified Rankin Scale(mRS);Magnetic Resonance Spectroscopy(MRS);

Countries

China

Contacts

Public ContactQingmei Chen

Department of Rehabilitation Medicine, the First Affiliated Hospital of Soochow University

dingx0925@163.com+86 512 6778 0393

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026